Servier Unveils €200M Strategic Venture Fund to Back Next-Gen Biotech…

Team S · 2026-01-09T14:55:48.000Z

French pharmaceutical group Servier has launched Servier Ventures, a new strategic corporate venture capital fund aimed at accelerating innovation in biotech and therapeutic technologies, with an initial commitment of €200 million to invest primarily in European startups shaping the future of oncology and neurology. The fund marks a significant expansion of Servier’s long-term innovation strategy, reinforcing its role not only as a global drug developer but also as an early-stage supporter of breakthrough science and technology companies advancing treatments for diseases with high unmet medical needs. Servier Ventures will operate as a wholly-owned subsidiary of the Servier Group and will make minority equity investments in biotechs and tech-enabled life sciences companies, particularly those developing transformative therapeutic modalities, next-generation platforms, and breakthrough drug discovery tools. The fund is designed to complement Servier’s internal R&D efforts which already include broad scientific collaborations by supporting external innovation that can accelerate the development of new medicines and improve patient outcomes. Initially focused on oncology and neurology, the fund could expand into additional therapeutic areas and geographies over time as opportunities evolve. At the helm of this new initiative is Alexis Vandier, who has been named Global Head of Servier Ventures and will lead the fund’s investment strategy, portfolio development and external partnerships. Under his leadership, the team will work closely with founders and scientists to scale early-stage companies and integrate knowledge from Servier’s global research, regulatory and commercial infrastructure, driving deeper engagement between corporate resources and entrepreneurial innovation. The fund’s creation aligns with Servier’s overarching goal of championing scientific breakthroughs while enhancing its competitive edge in global healthcare innovation. Servier, governed by a non-profit foundation, has a long history of focusing on therapeutic progress and sustained investment in R&D, including collaborative ventures and open innovation initiatives. With the launch of Servier Ventures, the company is strategically positioning itself as a venture investor of choice for emerging biotech and therapeutic startups, bridging the gap between scientific discovery and clinical impact. #ServierVentures, #CorporateVC, #BiotechInvestment, #VentureCapital, #OncologyInnovation, #NeurologyR&D, #LifeSciences, #StartupFunding, #HealthcareInnovation, #EuropeanStartups, #TherapeuticsTech, #EarlyStageVC, #AIinBiotech

Member Login Get Access

Servier Unveils €200M Strategic Venture Fund to Back Next-Gen Biotech… | Newnex